Treatment in Sepsis (SBITS) study. The plan for this study was to include a relatively homogeneous group of septic patients with a given degree of severity of sepsis and sepsis-induced multiorgan failure, with a predictable, moderate to severe mortality risk. The pathophysiological reasoning for application of ivIgG included neutralization of endotoxin, enhancement of phagocytosis, and modification of cytokine release from endotoxinor exotoxin-stimulated peripheral mononuclear blood cells (5) .
The primary objective of the SBITS study was to test whether ivIgG will reduce 28-day mortality in comparison to standard treatment in patients with a defined degree of sepsis severity (sepsis score 12-27) (6) and of sepsis-induced disease severity (Acute Physiology and Chronic Health Evaluation [APACHE] II score 20 -35) (7) . Serial scoring over the first 4 days after participants started the study medication was performed to quantify the impact on disease and sepsis severity. Changes in severity of disease are reflected by a decrease in the APACHE II score, while a decline in sepsis score mirrors resolution of sepsis. The concept and the published protocol of the SBITS study (8) formed the basis of a discussion forum titled Methodology of Clinical Trials in Sepsis (9) , whose helpful thoughts were integrated into the study approach. In vitro data from the literature argue for a suppression of proinflammatory cytokine production by ivIgG in activated human leukocytes (5, 10) . Consequently, we investigated the effects of ivIgG on plasma levels of interleukin (IL)-6 as well as soluble tumor necrosis factor receptors (sTNFR) p55 and p75 (11) .
MATERIALS AND METHODS

Study Population and Entry Criteria.
The trial was conducted in 23 medical and surgical centers in Germany that were part of a group of 25 classified study centers. From January 1991 to April 1995, 653 medical and surgical patients with sepsis were included in the SBITS study, and 647 of these patients met the inclusion criteria. The patients were selected according to criteria given in the prepublished protocol (8) , where they had to meet three conditions:
1. Four of nine positive sepsis criteria (12) : Temperature Ͼ38.5°C or Ͻ36°C White blood cell count Ͼ12 G/L or Ͻ3.5 G/L Heart rate Ͼ100 beats/min Respiratory rate Ͼ28 breaths/min or FIO 2 Ͼ0.21
Mean arterial pressure Ͻ75 mm Hg In case of invasive hemodynamic monitoring (not obligatory for study participation), cardiac index Ͼ4.5 L/min/m 2 or systemic vascular resistance Ͻ800 dyne/ sec/cm
Ϫ5
Platelets Ͻ100 G/L Positive blood cultures Clinical evidence of sepsis (surgical or invasive procedure during the preceding 48 hrs or presence of an obvious septic focus) 2. A sepsis score of 12-27, rating several variables categorized into four classes according to Elebute and Stoner (6): local signs of infection, pyrexia, organ failure, and laboratory values 3. An APACHE II score of 20 -35 as a measure of the degree of disease severity
As published in detail previously (12) , the score computer algorithm followed the original APACHE II calculation with the exception of Glasgow Coma Scale (GCS) assessment in sedated patients. In these patients, the best rather than the worst GCS value was recorded.
The primary end point was reduction in mortality from all causes at day 28 after administration of the study drug on day 0 and on day 1. Secondary end points included reduction in 7-day mortality; resolution of sepsis from day 0 to day 4, as measured by a decrease in sepsis score (6) and by a decline in the number of positive sepsis criteria from day 0 to day 4; and resolution in severity of disease, as measured by a decrease in APACHE II score (7) from day 0 to day 4. Further secondary end points were a reduced need for mechanical ventilation and improvement of lung function, as measured by the alveolar-arterial oxygen ratio (PAO 2 Ϫ PaO 2 ):PAO 2 (13) at day 4 in the study groups. Additional efficacy variables were 4-day survival, survival on the intensive care unit (ICU), and mean durations of mechanical ventilation, ICU stay, and hospital stay. The protocol was approved by the institutional review board at each participating center, and written informed consent was obtained from all patients or-in accordance with the Declaration of Helsinki-from the next of kin as patients' legal representatives. The study was monitored by an independent scientific and safety committee (Appendix) .
Randomization Process and Treatment. Patients were uniformly assessed in all centers with a program mounted on a pocket computer that all centers had been equipped with (12) and were randomly assigned in a doubleblind fashion to receive one of two solutions: 1) a commercially available 5% solution of ivIgG (Polyglobin N, Bayer Biological Products, Leverkusen, Germany) at a total dose of 900 mg/kg of body weight, administered as 12 mL (600 mg)/kg of body weight on day 0 and 6 mL (300 mg)/kg of body weight on day 1; or 2) placebo consisting of 0.1% human serum albumin, identical in appearance to the ivIgG 5% solution, at a dose of 12 mL (12 mg)/kg of body weight on day 0 and 6 mL (6 mg)/kg of body weight on day 1.
To guarantee double-blind conditions, serial random numbers were used (8) . The identity of the medication that each patient received was marked on a card. A copy was forwarded as part of the confidential study documents to Troponwerke, Cologne. If the double-blind condition had to be lifted because of serious adverse event, the study monitor had to be informed immediately. The patient would be withdrawn from the course of the study and observed by the investigator.
Decisions about antimicrobial drug therapy, supportive care, and surgical interventions were made by the patient's attending physicians and were not dictated by the study protocol.
Evaluation of Patients. All patients were followed throughout the 28-day study period until discharge from the hospital or death.
Samples of blood and specimen from other suspected sites of infection were obtained for culture within 72 hrs before and/or after the administration of the study medication.
The primary source of infection, the causative pathogen, and the adequacy of antimicrobial therapy were determined in a blinded fashion by a critical care specialist, an infectious disease specialist, and a microbiologist, according to prospectively defined criteria (8) .
Primary source of infection was proven when clinical signs and local microbiological findings were concordant.
The causative pathogen was identified by positive blood culture. A blood culture was defined as positive if at least two blood samples carried the same species; it was defined as probably positive if one blood sample carried the species.
Adequate antimicrobial therapy was defined as the administration of at least one drug to which the causative organism was susceptible within 24 hrs after the onset of sepsis. Pseudomonas pneumonia required at least two active drugs, and polymicrobial abdominal infections required a drug active against enteric anaerobic bacteria.
Evaluation of secondary efficiency variables was carried out on days 4 and 7: day 4, APACHE II score, sepsis score, sepsis criteria, alveolar-arterial oxygen ratio (PAO 2 Ϫ PaO 2 ): PAO 2 , 7-day mortality.
APACHE II score, sepsis score, and sepsis criteria were calculated bedside as enrollment criteria, and on day 4, as described previously.
Plasma sampling (heparin plasma) for the measurement of IgG, IL-6, and tumor necrosis factor receptors (TNFR) I (p55) and II (p75) was carried out before application of the first test drug on day 0, at 4 hrs after the second administration of the test drug (day 1), and on day 4; samples were kept frozen at Ϫ80°C until analysis by standard tests.
Statistical Analysis. Data management included double data entry and provided for comprehensive plausibility checking. Before further data procession, all data were audited by an external project monitor. The group sizes (2 ϫ 400 patients) were calculated to detect a reduction in mortality from 30% to 20% (Ϫ33% of reference) with a global significance level of 5% and a power of 90%. The treatment groups were compared regarding age, gender, body weight, score points (APACHE II score, sepsis score), type of patients (surgical, medical), and serum bilirubin. For these comparisons, the chi-square test or analyses of variance were planned, each with an ␣ ϭ .05.
Calculation of the primary efficacy variable was done by the stratified exact Fisher's test. For the primary efficacy variable, a log-linear model with the three categorical variablestreatment, center, and 28-day mortality-was used.
To support the results of the primary variable, the following secondary variables were to be tested in an exploratory manner: mortality within 7 days posttreatment, APACHE II score, sepsis score, number of positive sepsis criteria, need for mechanical ventilation, and alveolararterial oxygen ratio (PAO 2 Ϫ PaO 2 ):PAO 2 .
Other variables were added in an exploratory manner during the course of the statistical evaluation: 4-day survival, numbers of patients surviving on ICU, mean duration of ICU treatment, mean duration of mechanical ventilation, and mean duration of hospitalization.
In addition, descriptive p values were calculated for a number of subgroup analyses and for factors thought to influence the outcome.
In the analysis of scores and the alveolararterial oxygen ratio, as well as of discharge from the ICU or hospital, data on patients who died during the study period were censored (i.e., the patients were considered to have the highest scores seen during the course of the individual patients in the ICU and in the hospital) at 28 days.
Plasma levels of IgG, IL-6, and sTNF I and II were analyzed descriptively.
RESULTS
Comparison of the Study Groups.
Twenty-three study centers included 653 medical and surgical patients with sepsis defined by a sepsis score of 12-27 and an APACHE II score of 20 -35. Of these patients, 647 met the inclusion criteria, of whom 23 presented with predefined exclusion criteria. Thus, the per-protocol evaluation group consisted of 624 patients.
Three hundred and twenty-one patients were assigned to the ivIgG group and 303 patients were assigned to the placebo group. Table 1 compares the baseline characteristics of the two groups and shows that both groups were balanced, with the exception of gender, with a slightly but significantly (p ϭ .04) higher proportion of female patients in the placebo group (33.3%) than in the ivIgG group (25.5%).
Serum IgG Levels in the ivIgG and Placebo Groups During the Initial 4-Day
Period. On day 0, the mean IgG values were in the low normal range. In the ivIgG group, IgG levels rose sharply after ivIgG application on day 0 and day 1, up to the supranormal range on day 1 (Fig.  1) . The IgG levels remained in the high normal range at least until day 4, when the last measurement took place. No difference was seen in IgG levels of survivors and nonsurvivors (28-day mortality) in the placebo group; in the ivIgG group, however, IgG levels on day 4 were slightly but significantly higher in survivors compared with nonsurvivors.
28-Day Mortality as the Primary End Point of the SBITS Study.
With respect to the primary end point of the SBITS study, no significant difference (p ϭ .6695) was found in 28-day mortality rates of 39.3% (126 of 321) in the ivIgG group and 37.3% (113 of 303) in the placebo group. Figure 2 presents Kaplan-Meier survival curves for the ivIgG group and the placebo group.
As gender was slightly unbalanced in the placebo and ivIgG groups (Table 1) , the study population was analyzed separately by gender: 28-day mortality in female patients was 33.9% (62 of 183) and in male patients 40.1% (177 of 441). Death occurred in 100 of the 239 (41.8%) male patients in the ivIgG group and 77 of the 202 (38.1%) male patients in the placebo group. With respect to the female patients, 26 of the 82 (31.7%) died in the ivIgG group and 36 of the 101 (35.6%) died in the placebo group.
Effects of ivIgG on Secondary End Points. The 7-day survival rate in the ivIgG group was not significantly different from the placebo group (Table 2) .
The majority of patients were mechanically ventilated at baseline (90.5%). No beneficial effect of ivIgG treatment on pulmonary function (alveolar-arterial oxygen ratio and percentage of ventilated patients) could be observed within the first 4 days after patients started ivIgG treatment.
In assessing disease severity, a significantly stronger decline of the sepsis score (Ϫ1.21) in the ivIgG group compared with placebo and a similar change in the sepsis criteria argue for a moderate improvement by ivIgG in the degree of sepsis. The more pronounced decline in APACHE II score (Ϫ1.25) in the ivIgG group compared with placebo reached borderline significance, arguing for a moderate improvement by ivIgG in disease severity. With respect to the APACHE II score findings, the stronger score decline in the ivIgG group compared with placebo was mainly due to two of the individual score components: first, leukocytes decreased in the ivIgG group (Ϫ1.29 Ϯ 9.1 G/L) and increased further in the placebo group (1.07 Ϯ 9.3 G/L; p ϭ .004), and second, GCS score improved due to improved motor response more in the ivIgG group (0.44 Ϯ 1.9) than in the placebo group (Ϫ0.06 Ϯ 1.9; p ϭ .002).
Exploratory Findings Including Subgroup Analysis in the SBITS Study. The 4-day survival rate was not significantly different in both groups ( Table 2 ). The total duration of mechanical ventilation was significantly shorter in the ivIgG group compared with the placebo group. Survival rate in the ICU was approximately 6% higher in the ivIgG group than in the placebo group.
Looking for subgroup analysis in an exploratory manner, we found no significant difference in mortality for patients with Gram-negative infections or Grampositive infections, patients with positively proven and highly probable bacteremia, patients with peritonitis, surgical patients, and medical patients.
Effects of ivIgG on Plasma Levels of IL-6 and sTNFR I and II. There were no significant differences between the study and the placebo group at baseline and on days 1 and 4 after onset of treatment (Table 3) .
Adverse Events. In total, 19 adverse events were reported in 17 patients, with 6 adverse events in 6 patients of the placebo group and 13 adverse events in 11 patients of the ivIgG group (p ϭ .39) ( Table 4) . Three of the adverse events occurring in the placebo group and six in the ivIgG group were defined as skin reactions (erythema, exanthema). All the patients suffering from adverse events as well as the one showing an anaphylactic reaction were receiving antibiotic treatment at the time of the event.
DISCUSSION
Effects of ivIgG on Mortality in Patients with Sepsis. Until the conduct of the SBITS study, only data from relatively small controlled ivIg trials in sepsis were available (14, 15) . The most promising of these trials were the ones by Dominioni (16, 17) , documenting a reduction in Table 1 . mortality by 36% (from 64% to 33%) with the application of ivIgG in patients with postoperative sepsis and a sepsis score Ն17 (n ϭ 113), and by Schedel (18 -20) , documenting a reduction in mortality by 88% (from 32% to 4%) with the application of ivIgGMA in patients with septic shock and endotoxemia of Ͼ12.5 pg/mL (n ϭ 55). Based on subgroup meta-analyses of 11 ivIg sepsis trials, with the relatively small number of 492 patients in all, the Cochrane Institution (21) The authors of this meta-analysis concluded that ivIg has a promising role as adjuvant therapy in sepsis in adults but that large, multicenter studies are needed to confirm the positive results found in relatively small trials.
The SBITS study is the largest placebocontrolled, randomized, double-blinded, multicenter ivIgG trial, representing a broad spectrum of medical and surgical severe sepsis and septic shock (22) (Table  1) . Due to the score inclusion criteria, uncomplicated sepsis without severe organ dysfunction-like urosepsis-is represented only to a small degree (Table 1) . Antibiotic treatment was adequate or probably adequate in Ն90% of cases, and the microbiological spectrum was typical ( Table 1) .
The ivIgG dose regimen was sufficient to raise the plasma IgG level from the low normal range within 24 hrs to the supranormal range, with adequate IgG plasma levels for Ն4 days (Fig. 1) . However, there were no significant IgG level differences between survivors and nonsurvivors. Thus, our findings do not support the postulated prognostic relevance of plasma IgG level in sepsis (23) .
As the main result, the SBITS study revealed no reduction in mortality by application of ivIgG (Fig. 2) in the total study population as well as in subgroups. With 624 patients evaluated, this negative result relies on a sufficient statistical power for a disease with an assumed mortality of about 40% (8, 24, 25) . The discrepancy between no mortality reduction by ivIgG in SBITS vs. mortality reduction reported in smaller trials (14, 21) remains unexplained. Given the statistical power of SBITS, the study data do not nourish the hope that ivIgG is a "magic bullet" for supplemental sepsis therapy. Recently, this was further supported by another randomized, placebo-controlled, large trial from our group in postcardiac surgery patients with severe SIRS (ESSICS) (K Werdan et al., unpublished data). The teams of the SBITS and ESSICS studies opted to submit both articles together. The raw data had been accessible to the public in abstract form and via the Cochrane Library in advance. The delay in publishing the full-length paper is due to circumstantial factors (like part of the team moving places) and well-known human shortcomings.
Failure of ivIgG to reduce sepsis mortality does not necessarily exclude a survival benefit of ivIgGMA preparations, as claimed in the Cochrane meta-analysis (21) . Of note, the ivIgG dose regimen recommended for sepsis and applied in SBITS (0.9 g/kg) is only the moiety compared with other indications like immune thrombocytopenia or streptococcal toxic shock syndrome (2 g/kg) (26, 27) . The positive findings in patients with streptococcal toxic shock syndrome cannot be put into question by the SBITS trial. Also, the findings of the SBITS study do not preclude possible benefits of high-dose ivIgG in sepsis. With the progress seen in intensive care medicine in the last years, particularly in the treatment of critically ill sepsis patients, it cannot be ruled out that newer regimens would change the overall result of ivIgG treatment, although this seems unlikely. Why did ivIgG treatment in the SBITS study fail to reduce mortality? From the many immunologic actions exerted by endogenous and exogenously applied immunoglobulins (10), neutralization of endotoxin-IgM being more potent than IgG (28, 29) -and attenuation of the overshooting inflammation are likely beneficial mechanisms in sepsis (14) . In vitro experiments show ivIgGinduced modulation of cytokine production by leukocytes activated with toxins from Gram-negative and Grampositive pathogens (5, 27, 30, 31) . Our study allows testing of this phenomenon in the clinical arena. Plasma levels of IL-6 as well as of TNFR I and II are expectedly high; those of IL-6 decrease within 4 days; and those of TNFR I and II remain constant, both in the total study group (Table 3 ) and in an SBITS subgroup without renal failure (32) . Surprisingly, ivIgG application had no significant effect on the elevated plasma levels of IL-6, TNFR I, and TNFR II in SBITS. This finding was confirmed in our ESSICS trial (discussed previously). Very recent observations attribute a major role to the subset of catalytic antibodies in the recovery from sepsis, which may be more important than the overall antibody levels for survival and could thus explain the failure of 0.9 g/kg ivIgG to attenuate the proinflammatory state (M Kazatchkine, personal communication, 2006) . Also, it cannot be ruled out that a higher dose of ivIgG could still produce some immunologic and clinical effect.
Effects of ivIg on Morbidity in Patients With Sepsis: Prognosis-Related Morbidity Measures as End Points of Clinical Sepsis
Trials. The SBITS study stands in a long row of clinical sepsis trials using antiinflammatory substances with no reduction in mortality (4, 25, 33) . To prove smaller mortality reduction (by 10%), trials enrolling 6,000 -7,000 septic patients would be needed (4) . These requirements challenge the feasibility of clinical sepsis trials (34) . In previous work we have characterized the decrease in APACHE II score by four points from day 0 to day 4 as a powerful mortality-associated improvement index (35) . The SBITS study prospectively confirms the prognostic value of sequential scoring, with a decrease in the APACHE II score within 4 days in survivors by 5.9 vs. no relevant change (0.4) in nonsurvivors (Fig. 3) .
Regarding the effect of ivIgG on morbidity, SBITS shows a more pronounced decrease in APACHE II score and in sepsis score in the ivIgG group compared with placebo (Table 2) . However, this improvement in disease and sepsis severity by ivIgG was only slight and failed to translate into an impact on mortality. As a clinical correlate of this slight effect we found a shorter duration of mechanical ventilation (2.1 days in the ivIgG group).
What underlies the ivIgG effect on morbidity? A lower leukocyte count, a lower plasma bilirubin level, and a better GCS score characterize the ivIgG group on day 4. The improvement in the GCS score is exclusively due to the better motor response (Table 2) , which in all caution might indicate some improvement in skeletal muscle function. In this context, a retrospective chart analysis suggested that early ivIgGMA application may prevent or mitigate critical illness polyneuropathy in patients with Gramnegative sepsis and multiple organ failure (36) . In analogy, we may speculate that in the SBITS study, the ivIgG-correlated amelioration in the motor response might be accounted for by an effect on critical illness neuropathy. Likewise, an ivIgG-induced prevention of critical illness neuropathy and impaired motor response offers a possible explanation for the shorter duration of mechanical ventilation in this group, particularly given the absence of any ivIgG effect on lung function (Table 2) .
CONCLUSIONS
The SBITS study shows no reduction in mortality by ivIgG in patients with score-defined sepsis and sepsis-induced multiorgan failure. A slight improvement of sepsis and disease severity of uncertain clinical relevance could be demonstrated. 
